Jun 14 |
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
|
Jun 14 |
Employer coverage for GLP-1s rising amid FDA label expansions: survey
|
Jun 14 |
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
|
Jun 14 |
Zacks Market Edge Highlights: CAVA, Abercrombie & Fitch, Eli Lilly, CrowdStrike and Deckers Outdoor
|
Jun 14 |
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
|
Jun 13 |
5 Hot Growth Stocks: Buy on the Highs or Wait for a Pullback?
|
Jun 13 |
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
Jun 13 |
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
|
Jun 13 |
Billionaire Israel Englander is Buying This Weight Loss Stock in 2024
|
Jun 13 |
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
|